Sarepta Therapeutics Inc. (NASDAQ:SRPT) – Equities researchers at SunTrust Banks reduced their Q3 2016 EPS estimates for Sarepta Therapeutics in a research note issued on Tuesday. SunTrust Banks analyst E. Nash now anticipates that the brokerage will earn ($1.28) per share for the quarter, down from their previous forecast of ($1.12). SunTrust Banks currently has a “Neutral” rating on the stock. SunTrust Banks also issued estimates for Sarepta Therapeutics’ Q4 2016 earnings at ($1.22) EPS, FY2016 earnings at ($5.20) EPS, FY2017 earnings at ($2.70) EPS, FY2018 earnings at ($1.40) EPS, FY2019 earnings at ($0.42) EPS and FY2020 earnings at $0.52 EPS.

A number of other research firms also recently weighed in on SRPT. JMP Securities upgraded Sarepta Therapeutics to an “outperform” rating and upped their target price for the stock from $10.00 to $60.00 in a research report on Monday. Oppenheimer Holdings Inc. upped their target price on Sarepta Therapeutics from $60.00 to $76.00 in a research report on Monday. Cowen and Company upgraded Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $64.00 target price for the company in a research report on Tuesday. Wedbush restated an “outperform” rating and issued a $66.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday. Finally, Needham & Company LLC upped their target price on Sarepta Therapeutics from $47.00 to $81.00 and gave the stock a “buy” rating in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $48.70.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 60.97 on Thursday. The firm’s market cap is $2.92 billion. The stock’s 50 day moving average price is $30.01 and its 200 day moving average price is $21.91. Sarepta Therapeutics has a 12-month low of $8.00 and a 12-month high of $61.60.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same period last year, the business posted ($0.87) earnings per share.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Teacher Retirement System of Texas raised its position in shares of Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock worth $115,000 after buying an additional 724 shares in the last quarter. Advisor Group Inc. acquired a new position in Sarepta Therapeutics during the second quarter valued at about $154,000. Quantitative Systematic Strategies LLC acquired a new position in Sarepta Therapeutics during the second quarter valued at about $211,000. National Planning Corp raised its position in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock valued at $242,000 after buying an additional 275 shares during the period. Finally, First Allied Advisory Services Inc. raised its position in Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock valued at $245,000 after buying an additional 800 shares during the period. 72.09% of the stock is owned by institutional investors and hedge funds.

In other news, VP Jayant Aphale sold 35,000 shares of the company’s stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $50.00, for a total transaction of $1,750,000.00. Following the completion of the transaction, the vice president now owns 21,490 shares of the company’s stock, valued at $1,074,500. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Edward M. Md Kaye sold 24,352 shares of the company’s stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $50.00, for a total transaction of $1,217,600.00. Following the transaction, the chief executive officer now directly owns 89,983 shares of the company’s stock, valued at approximately $4,499,150. The disclosure for this sale can be found here. Company insiders own 10.90% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.